By Fineline Cube ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG: 1541) announced it has received clinical approval from China’s National Medical Products Administration (NMPA) for its dual-target macromolecular drug amulirafusp alfa (IMM0306) to proceed with clinical evaluation in primary Sjögren’s syndrome (pSS).
Development & Regulatory Milestone
| Parameter | Detail |
|---|---|
| Company | ImmuneOnco Biopharmaceuticals (HKG: 1541) |
| Drug Candidate | Amulirafusp alfa (IMM0306) |
| Drug Class | CD47×CD20 bispecific molecule |
| Innovation Status | World’s first CD47×CD20 bispecific in clinical development |
| Technology Platform | Proprietary “mAb-Trap” technology |
| New Indication | Primary Sjögren’s syndrome (pSS) |
| Regulatory Authority | NMPA (China) |
| Approval Type | Clinical study authorization |
Disease Profile & Unmet Need
Primary Sjögren’s Syndrome (pSS)
- Disease characterization: Chronic, systemic autoimmune disorder predominantly featuring lymphocytic infiltration of exocrine glands
- Patient impact: Severely compromises quality of life through dry eyes, dry mouth, fatigue, and systemic complications
- Treatment gap: Limited therapeutic options with no disease-modifying treatments currently approved
- Market opportunity: Estimated 4 million patients globally, with significant prevalence in Asia-Pacific region
Drug Profile & Mechanism Innovation
Proprietary “mAb-Trap” Technology
IMM0306 represents a first-in-class bispecific approach leveraging ImmuneOnco’s proprietary platform:
| Target | Function | Therapeutic Rationale |
|---|---|---|
| CD47 | “Don’t eat me” signal on immune cells | Blockade enhances phagocytosis of pathogenic B-cells |
| CD20 | B-cell surface marker | Direct targeting of autoreactive B-cell populations |
| Bispecific design | Simultaneous dual targeting | Enhanced specificity and reduced off-target effects compared to monospecific approaches |
Clinical Validation Foundation
- SLE Phase Ib/II data: Demonstrated favorable safety profile and strong therapeutic potential in systemic lupus erythematosus
- IgG4-RD evaluation: Currently being assessed in IgG4-related disease, validating platform across multiple autoimmune conditions
- Mechanistic rationale: Dual targeting addresses both B-cell depletion and immune checkpoint modulation simultaneously
Expanded Clinical Development Strategy
Multi-Indication Platform Approach
The pSS approval extends IMM0306’s clinical program across three distinct autoimmune diseases:
| Indication | Development Stage | Strategic Rationale |
|---|---|---|
| Systemic Lupus Erythematosus (SLE) | Phase Ib/II completed | Proof-of-concept for bispecific mechanism in systemic autoimmunity |
| IgG4-Related Disease (IgG4-RD) | Ongoing studies | Validation in fibroinflammatory condition |
| Primary Sjögren’s Syndrome (pSS) | Newly approved | Addressing high-unmet-need exocrine gland autoimmune disorder |
Competitive Differentiation
- First-mover advantage: World’s first CD47×CD20 bispecific provides significant intellectual property protection
- Safety optimization: Bispecific design potentially reduces CD47-related hematological toxicity seen with monospecific CD47 inhibitors
- Platform validation: Success across multiple indications would validate “mAb-Trap” technology for broader application
Strategic Implications & Market Context
For ImmuneOnco
- Pipeline diversification: Expands beyond oncology into high-value autoimmune therapeutic area
- Platform validation: Multiple indication success would demonstrate broad applicability of proprietary technology
- Global potential: First-in-class status positions for international partnerships and regulatory submissions
Autoimmune Disease Landscape
- B-cell targeting evolution: Next-generation approaches moving beyond simple B-cell depletion to precision immune modulation
- Combination potential: Bispecific mechanism may enable monotherapy efficacy where combination regimens currently required
- Chinese innovation leadership: Represents China’s growing capability in complex biologic development for global markets
The pSS clinical approval positions IMM0306 as a transformative therapeutic candidate for a disease with significant unmet medical need, while validating ImmuneOnco’s innovative bispecific platform across multiple autoimmune conditions.
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory pathways, and therapeutic potential for IMM0306. Actual results may differ due to risks including clinical trial outcomes, safety profile, and competitive dynamics.-Fineline Info & Tech